drugset / Trial / NCT03521505

Dexmedetomidine for Sedation of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration

NCT03521505

Phase 4 Completed 50 enrolled Chang Gung Memorial Hospital
RandomizedParallel-groupOpen-labelOther

Summary

Preventing hypoxemia is one of the major goal of studies for bronchoscopic sedation. Dexmedetomidine is a sedative agents via α2 adrenergic agonist, with little respiratory suppression. In the preset study, we evaluate the safety and feasibility of the Dexmedetomidine in the specific bronchoscopic procedure, endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration.

Timeline

Start
2018-05-11
Primary completion
2020-01-22
Completion
2020-01-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 0.5 ug/kg
Subject Dexmedetomidine Other / unclassified 1.4 ug/kg
Comparator Propofol Small molecule 2 ug/ml Intravenous
Comparator Alfentanil Other / unclassified 5 mg/kg

Indications

No indication recorded.